Glenmark Pharmaceuticals receives USFDA approval for Clobetasol Propionate Foam, 0.05%

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending July 2019, the Olux‐E Foam, 0.05% market2 achieved annual sales of approximately $11.1 million.

Powered by Capital Market - Live News